Upexi (UPXI) Competitors

Upexi logo
$3.69 +0.14 (+3.94%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$3.80 +0.12 (+3.12%)
As of 08:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UPXI vs. SLGL, ATHA, NKGN, GLYC, AFMD, SPRB, HCWB, SYBX, EGRX, and NRSN

Should you be buying Upexi stock or one of its competitors? The main competitors of Upexi include Sol-Gel Technologies (SLGL), Athira Pharma (ATHA), NKGen Biotech (NKGN), GlycoMimetics (GLYC), Affimed (AFMD), Spruce Biosciences (SPRB), HCW Biologics (HCWB), Synlogic (SYBX), Eagle Pharmaceuticals (EGRX), and NeuroSense Therapeutics (NRSN). These companies are all part of the "pharmaceutical products" industry.

Upexi vs.

Sol-Gel Technologies (NASDAQ:SLGL) and Upexi (NASDAQ:UPXI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, community ranking, dividends, media sentiment, valuation and earnings.

Sol-Gel Technologies has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Upexi has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500.

Upexi has higher revenue and earnings than Sol-Gel Technologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sol-Gel Technologies$1.55M10.84-$27.24M-$0.34-1.77
Upexi$26M0.18-$23.66MN/AN/A

In the previous week, Upexi had 1 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 3 mentions for Upexi and 2 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 1.19 beat Upexi's score of 0.17 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sol-Gel Technologies
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Upexi
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Sol-Gel Technologies currently has a consensus target price of $5.00, indicating a potential upside of 729.19%. Upexi has a consensus target price of $25.00, indicating a potential upside of 577.51%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Sol-Gel Technologies is more favorable than Upexi.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sol-Gel Technologies
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Upexi
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Upexi has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -81.75%. Upexi's return on equity of 0.00% beat Sol-Gel Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Sol-Gel Technologies-81.75% -27.17% -22.49%
Upexi N/A N/A N/A

Sol-Gel Technologies received 146 more outperform votes than Upexi when rated by MarketBeat users. Likewise, 63.40% of users gave Sol-Gel Technologies an outperform vote while only 42.86% of users gave Upexi an outperform vote.

CompanyUnderperformOutperform
Sol-Gel TechnologiesOutperform Votes
149
63.40%
Underperform Votes
86
36.60%
UpexiOutperform Votes
3
42.86%
Underperform Votes
4
57.14%

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 34.7% of Upexi shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Sol-Gel Technologies beats Upexi on 10 of the 16 factors compared between the two stocks.

Get Upexi News Delivered to You Automatically

Sign up to receive the latest news and ratings for UPXI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UPXI vs. The Competition

MetricUpexiMedicinals & botanicals IndustryBusiness SectorNASDAQ Exchange
Market Cap$4.88M$1.21B$7.99B$9.16B
Dividend YieldN/AN/A2.21%4.00%
P/E RatioN/A22.6726.9614.33
Price / Sales0.185.8293.9373.99
Price / CashN/A10.8831.4538.87
Price / Book0.591.816.125.00
Net Income-$23.66M-$53.22M$143.06M$222.75M
7 Day Performance-6.11%-4.49%0.33%-1.01%
1 Month Performance0.82%-1.73%3.53%4.04%
1 Year Performance-85.70%-10.97%24.17%21.71%

Upexi Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UPXI
Upexi
2.3104 of 5 stars
$3.69
+3.9%
$25.00
+577.5%
-84.8%$4.88M$26M0.00130Short Interest ↑
Gap Down
SLGL
Sol-Gel Technologies
3.4881 of 5 stars
$0.65
+3.2%
$5.00
+668.5%
-53.6%$18.12M$11.71M-1.9150Short Interest ↓
Positive News
Gap Down
ATHA
Athira Pharma
3.7838 of 5 stars
$0.44
-7.5%
$13.83
+3,036.1%
-86.1%$17.06MN/A-0.1540Upcoming Earnings
Short Interest ↓
Positive News
NKGN
NKGen Biotech
N/A$0.38
-12.1%
N/A-48.0%$16.90M$80,000.00-0.07N/ANews Coverage
Gap Up
GLYC
GlycoMimetics
4.4015 of 5 stars
$0.26
-1.7%
$8.00
+2,968.7%
-91.6%$16.81M$10,000.000.0050Analyst Forecast
Short Interest ↓
Gap Down
AFMD
Affimed
4.3114 of 5 stars
$1.04
-1.0%
$13.50
+1,198.1%
-83.1%$16.74M$877,000.000.00200Positive News
SPRB
Spruce Biosciences
4.0635 of 5 stars
$0.40
-2.2%
$3.90
+882.4%
-90.7%$16.40M$10.09M-0.4220Short Interest ↓
Gap Down
HCWB
HCW Biologics
0.797 of 5 stars
$0.42
-13.1%
N/A-64.6%$16.03M$2.84M-0.4240Short Interest ↑
SYBX
Synlogic
2.4788 of 5 stars
$1.35
+0.7%
N/A-20.9%$15.79M$2.78M-0.3280Positive News
EGRX
Eagle Pharmaceuticals
N/A$1.19
+32.2%
N/A-78.9%$15.46M$316.61M0.00100News Coverage
Gap Down
NRSN
NeuroSense Therapeutics
1.2863 of 5 stars
$1.13
-2.6%
N/A-9.6%$15.45MN/A-1.7710Short Interest ↓

Related Companies and Tools


This page (NASDAQ:UPXI) was last updated on 2/13/2025 by MarketBeat.com Staff
From Our Partners